Realta Investment Advisors cut its position in shares of Astera Labs, Inc. (NASDAQ:ALAB – Free Report) by 55.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,060 shares of the company’s stock after selling 2,595 shares during the period. Realta Investment Advisors’ holdings in Astera Labs were worth $290,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of ALAB. Hollencrest Capital Management bought a new position in Astera Labs during the third quarter worth about $26,000. Geneos Wealth Management Inc. bought a new position in shares of Astera Labs during the 4th quarter worth approximately $36,000. ORG Wealth Partners LLC bought a new position in shares of Astera Labs during the 4th quarter worth approximately $42,000. US Bancorp DE acquired a new position in shares of Astera Labs during the 3rd quarter worth approximately $46,000. Finally, First Horizon Advisors Inc. bought a new stake in Astera Labs in the 3rd quarter valued at $49,000. 60.47% of the stock is owned by institutional investors.
Insider Buying and Selling
In other Astera Labs news, Director Manuel Alba sold 11,000 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $117.50, for a total value of $1,292,500.00. Following the sale, the director now owns 456,863 shares of the company’s stock, valued at approximately $53,681,402.50. This trade represents a 2.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Philip Mazzara sold 2,513 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $90.81, for a total value of $228,205.53. Following the transaction, the general counsel now directly owns 248,745 shares of the company’s stock, valued at $22,588,533.45. This trade represents a 1.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 846,452 shares of company stock worth $86,427,256.
Astera Labs Stock Down 3.1 %
Analyst Ratings Changes
A number of equities analysts have commented on ALAB shares. Roth Mkm upped their price objective on shares of Astera Labs from $80.00 to $105.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Barclays upped their price target on shares of Astera Labs from $87.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Citigroup started coverage on shares of Astera Labs in a research report on Monday, November 18th. They set a “buy” rating and a $120.00 price objective for the company. Morgan Stanley decreased their target price on Astera Labs from $142.00 to $114.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 28th. Finally, Craig Hallum lifted their price target on Astera Labs from $75.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $107.42.
Check Out Our Latest Research Report on Astera Labs
Astera Labs Company Profile
Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.
Featured Articles
- Five stocks we like better than Astera Labs
- The Most Important Warren Buffett Stock for Investors: His Own
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- How to trade using analyst ratings
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- How to Invest in Biotech Stocks
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB – Free Report).
Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.